{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:23:10Z","timestamp":1763194990738,"version":"3.45.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In a subset of patients with systemic mastocytosis (SM), an associated hematologic neoplasm (AHN) is identified. Most AHN are myeloid neoplasms, whereas lymphoid neoplasms are uncommon. We report on a 70-year-old female patient with bone marrow mastocytosis (BMM) associated with primary cutaneous follicle center lymphoma (PCFCL). Initially, the patient had developed BMM at the age of 61 years. Since then, she suffered from recurrent anaphylaxis and vitiligo. A BM investigation revealed several compact aggregates of MC exhibiting CD25 and the\n                    <jats:italic>KIT<\/jats:italic>\n                    mutation D816V. The basal serum tryptase level ranged between 26.0 and 30.9 ng\/ml. Nine years after the initial diagnosis of BMM, the patient developed cutaneous nodular reddish lesions on her scalp. Histologic examination excluded mastocytosis and revealed PCFCL. Radiation therapy resulted in regression of cutaneous lesions. This unusual case demonstrates that patients with BMM may develop a lymphoid neoplasm in extramedullary sites, including skin. However, both neoplasms were separable from each other by site and pathology, which would argue for two separate etiologies and against a classical AHN.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06588-4","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T02:57:12Z","timestamp":1757127432000},"page":"5543-5548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone marrow mastocytosis associated with primary cutaneous follicle center lymphoma: an unusual case report"],"prefix":"10.1007","volume":"104","author":[{"given":"Max Vincent","family":"John","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Griss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cora","family":"Waldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gaiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"6588_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny HP, Escribano L et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:603\u2013625. https:\/\/doi.org\/10.1016\/s0145-2126(01)00038-8","journal-title":"Leuk Res"},{"key":"6588_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-025-00611-8","volume":"11","author":"C Akin","year":"2025","unstructured":"Akin C, Arock M, Carter MC, George TI, Valent P (2025) Mastocytosis. Nat Rev Dis Primers 11:30. https:\/\/doi.org\/10.1038\/s41572-025-00611-8","journal-title":"Nat Rev Dis Primers"},{"key":"6588_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6588_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"6588_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","volume":"98","author":"SA Wang","year":"2023","unstructured":"Wang SA, Orazi A, Gotlib J et al (2023) The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol 98:1286\u20131306. https:\/\/doi.org\/10.1002\/ajh.26966","journal-title":"Am J Hematol"},{"key":"6588_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","volume":"482","author":"RJ Leguit","year":"2023","unstructured":"Leguit RJ, Wang SA, George TI, Tzankov A, Orazi A (2023) The international consensus classification of mastocytosis and related entities. Virchows Arch 482:99\u2013112. https:\/\/doi.org\/10.1007\/s00428-022-03423-3","journal-title":"Virchows Arch"},{"key":"6588_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41375-021-01406-y","volume":"36","author":"R Zanotti","year":"2022","unstructured":"Zanotti R, Bonifacio M, Lucchini G et al (2022) Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia 36:516\u2013524. https:\/\/doi.org\/10.1038\/s41375-021-01406-y","journal-title":"Leukemia"},{"key":"6588_CR8","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"55","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K et al (2021) Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere 55:e646. https:\/\/doi.org\/10.1097\/HS9.0000000000000646","journal-title":"Hemasphere"},{"key":"6588_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/jcp.2005.028837","volume":"59","author":"K Sotlar","year":"2006","unstructured":"Sotlar K, Saeger W, Stellmacher F et al (2006) Occult mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol 59:875\u2013878. https:\/\/doi.org\/10.1136\/jcp.2005.028837","journal-title":"J Clin Pathol"},{"key":"6588_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/0284186X.2021.1956689","volume":"60","author":"M Olszewska-Szopa","year":"2021","unstructured":"Olszewska-Szopa M, Sobas M, Laribi K et al (2021) Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature. Acta Oncol 60:1361\u20131368. https:\/\/doi.org\/10.1080\/0284186X.2021.1956689","journal-title":"Acta Oncol"},{"key":"6588_CR11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ajh.26968","volume":"98","author":"AC Hristov","year":"2023","unstructured":"Hristov AC, Tejasvi T, Wilcox RA (2023) Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:1326\u20131332. https:\/\/doi.org\/10.1002\/ajh.26968","journal-title":"Am J Hematol"},{"key":"6588_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jdcr.2023.03.015","volume":"36","author":"CM Kincaid","year":"2023","unstructured":"Kincaid CM, Phong C, Arnold JD et al (2023) Primary cutaneous lymphoma in a patient with mastocytosis: is there an association? JAAD Case Rep 36:70\u201372. https:\/\/doi.org\/10.1016\/j.jdcr.2023.03.015","journal-title":"JAAD Case Rep"},{"key":"6588_CR13","doi-asserted-by":"publisher","first-page":"2050313X2110425","DOI":"10.1177\/2050313X211042527","volume":"9","author":"HY Lee","year":"2021","unstructured":"Lee HY, Lee JS, Koo DW (2021) A case report of primary cutaneous marginal zone B-cell lymphoma with mastocytosis. SAGE Open Med Case Rep 9:2050313X211042527. https:\/\/doi.org\/10.1177\/2050313X211042527","journal-title":"SAGE Open Med Case Rep"},{"key":"6588_CR14","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bjd.12471","volume":"169","author":"KM Meyer","year":"2013","unstructured":"Meyer KM, Landthaler M, Hafner C, Geissinger E (2013) Systemic mastocytosis associated with cutaneous B-cell lymphoma. Br J Dermatol 169:1165\u20131167. https:\/\/doi.org\/10.1111\/bjd.12471","journal-title":"Br J Dermatol"},{"issue":"12","key":"6588_CR15","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","volume":"12","author":"P Valent","year":"2024","unstructured":"Valent P, Hartmann K, Hoermann G et al (2024) Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM. J Allergy Clin Immunol Pract 12(12):3250\u20133260e5. https:\/\/doi.org\/10.1016\/j.jaip.2024.08.044","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06588-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06588-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:17Z","timestamp":1763194757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06588-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6588"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06588-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,9,6]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Max Vincent John: no COI reported; Ingrid Simonitsch-Klupp: Honoraria: Takeda; Johannes Griss: Personal fees: AbbVie, Eli Lilly, Pfizer, Boehringer Ingelheim, Almirall, and Novartis; Harald Herrmann: no COI reported; Cora Waldstein: no COI reported; Alexander Gaiger: no COI reported; Karoline V. Gleixner: Honoraria: Jazz pharmaceuticals, AbbVie, Novartis, Servier, Blueprint Medicines, Incyte, Celgene Corporation, Astellas, Daiichi Sankyo; Wolfgang R. Sperr: (1) Consultancy and Honoraria: Thermo Fisher, AbbVie, Novartis, Pfizer, BMS\/Celgene, Blueprint, Incyte, Stemline, Servier, Jazz, Teva, (2) Research Grant: Pfizer; Peter Valent: (1) Research grant: AOP Orphan, (2) Advisory board and other consultant honoraria: Novartis, Blueprint Medicines, Cogent, Pfizer, AOP Orphan, Stemline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the patient prior to sampling and storage of cells in a local biobank. The storage of cells was approved by the ethics committee of the Medical University of Vienna (approval number: 1184\/2014). The patient gave written informed consent for publication of data and of the clinical photographs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}